Published in Am J Clin Pathol on May 01, 2008
Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol (2008) 2.29
Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol (2009) 1.40
C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol (2011) 1.15
Evaluation of adiposity-related biomarkers as metabolic syndrome indicators. Clin Nutr Res (2013) 0.86
C-reactive protein, high-molecular-weight adiponectin and development of metabolic syndrome in the Japanese general population: a longitudinal cohort study. PLoS One (2013) 0.82
Characterization of the ZDSD Rat: A Translational Model for the Study of Metabolic Syndrome and Type 2 Diabetes. J Diabetes Res (2015) 0.80
Relationship between plasma adiponectin level with inflammatory and metabolic markers in patients with chronic kidney disease. Nephrourol Mon (2013) 0.80
Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome. Cardiovasc Diabetol (2016) 0.78
Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome. Diabetol Metab Syndr (2014) 0.78
Inverse Association of Plasma IgG Antibody to Aggregatibacter actinomycetemcomitans and High C-Reactive Protein Levels in Patients with Metabolic Syndrome and Periodontitis. PLoS One (2016) 0.77
Inflammatory modulation of exercise salience: using hormesis to return to a healthy lifestyle. Nutr Metab (Lond) (2010) 0.77
Adiponectin as a Protective Factor Against the Progression Toward Type 2 Diabetes Mellitus in Postmenopausal Women. Medicine (Baltimore) (2015) 0.76
The Reversal Intervention for Metabolic Syndrome (TRIMS) study: rationale, design, and baseline data. Trials (2011) 0.76
Total and High Molecular Weight Adiponectin Levels and Prediction of Cardiovascular Risk in Diabetic Patients. Int J Endocrinol (2015) 0.75
Serum Adiponectin and Indices of Cardiovascular Risk in Young Women with Excessive Body Mass. EJIFCC (2010) 0.75
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 14.25
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab (2001) 9.53
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med (2002) 8.95
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation (2000) 7.37
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol (1999) 7.15
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2003) 5.40
Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol (2003) 4.86
Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem (2002) 4.79
Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem (2003) 4.08
Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation (2003) 3.73
Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet (2002) 3.68
C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation (2004) 3.25
Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes (2006) 3.14
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation (2004) 2.90
Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care (2006) 2.77
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation (2001) 2.60
Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes (2004) 2.51
Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem (2003) 2.29
The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr (2005) 2.23
Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia (2005) 1.69
Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes (2007) 1.63
Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol (1999) 1.51
Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes (2005) 1.50
A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta (2006) 1.44
C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia (2007) 1.18
Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am (2004) 1.17
Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia (2006) 1.11
Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol (2003) 1.07
Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab (2005) 1.01
C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol (2007) 0.94
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol (2006) 0.93
Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obes (Lond) (2007) 0.93
Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. Am Heart J (2006) 0.90
An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight pre-menopausal women. Clin Sci (Lond) (2007) 0.88
C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes (2006) 0.85
Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. Metabolism (2004) 0.83
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr (2002) 5.13
Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab (2004) 3.54
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab (2007) 2.84
Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab (2006) 2.73
Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr (2005) 2.72
Association of urinary pH with body weight in nephrolithiasis. Kidney Int (2004) 2.67
Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes (2006) 2.65
Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses. J Clin Endocrinol Metab (2009) 2.58
Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation (2002) 2.50
Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab (2010) 2.44
Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care (2010) 2.39
Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology (2011) 2.37
Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol (2008) 2.29
High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes (2008) 2.23
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension (2012) 2.23
Autophagy genes protect against Salmonella typhimurium infection and mediate insulin signaling-regulated pathogen resistance. Proc Natl Acad Sci U S A (2009) 2.21
Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res (2005) 2.18
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation (2003) 2.09
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation (2006) 2.06
Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. Am J Clin Nutr (2008) 2.05
Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol (2007) 2.02
Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology (2010) 1.96
Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord (2008) 1.95
Association of Hyperchloremia With Hospital Mortality in Critically Ill Septic Patients. Crit Care Med (2015) 1.93
Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology (2009) 1.92
Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine (2011) 1.91
Adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care (2003) 1.91
Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab (2011) 1.89
Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol (2008) 1.88
Retracted Alpha-lipoic acid supplementation and diabetes. Nutr Rev (2008) 1.86
Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging (2011) 1.86
High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab (2007) 1.85
Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes (2007) 1.84
Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. Am J Clin Nutr (2008) 1.83
Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int (2002) 1.78
Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab (2003) 1.74
Metabolic syndrome and the risk of calcium stones. Nephrol Dial Transplant (2012) 1.71
Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail (2011) 1.69
Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol (2012) 1.67
β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care (2012) 1.66
Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol (2006) 1.66
Open-cell versus closed-cell stent design differences in blood flow velocities after carotid stenting. J Vasc Surg (2009) 1.58
Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques. J Nutr (2013) 1.56
Hypercalciuria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab (2011) 1.54
Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem (2005) 1.53
Oxidative stress and atherosclerosis. Pathophysiology (2006) 1.52
Low prepregnancy adiponectin concentrations are associated with a marked increase in risk for development of gestational diabetes mellitus. Diabetes Care (2013) 1.52
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol (2008) 1.51
Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. Am J Clin Nutr (2005) 1.51
Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort. Circ Cardiovasc Genet (2012) 1.51
Body fat content and distribution and urinary risk factors for nephrolithiasis. Clin J Am Soc Nephrol (2013) 1.51
Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol (2009) 1.50
Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes (2005) 1.50
Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic lupus erythematosus. J Rheumatol (2002) 1.49
High prevalence of brown adipose tissue in adult humans. J Clin Endocrinol Metab (2011) 1.49
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
Effects of sugar-sweetened beverages on plasma acylation stimulating protein, leptin and adiponectin: relationships with metabolic outcomes. Obesity (Silver Spring) (2013) 1.46
Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab (2010) 1.45
Defining hypercalciuria in nephrolithiasis. Kidney Int (2011) 1.44
Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab (2009) 1.44
Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women. Arterioscler Thromb Vasc Biol (2004) 1.43
ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes (2005) 1.43
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.42
Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat. Am J Physiol Regul Integr Comp Physiol (2008) 1.41
Inducible brown adipogenesis of supraclavicular fat in adult humans. Endocrinology (2011) 1.41
Fructose consumption: recent results and their potential implications. Ann N Y Acad Sci (2010) 1.40
Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. Am J Physiol Renal Physiol (2013) 1.40
Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol (2009) 1.40
Quantification of daratumumab in the serum protein electrophoresis. Clin Chem Lab Med (2016) 1.39
Stimulated growth hormone concentrations in obese pediatric patients with mild and severe insulin resistance: a pilot study. J Pediatr Endocrinol Metab (2010) 1.39
Consumption of fructose-sweetened beverages for 10 weeks increases postprandial triacylglycerol and apolipoprotein-B concentrations in overweight and obese women. Br J Nutr (2008) 1.38
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care (2009) 1.38
CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol (2010) 1.37
Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes. Clin Transl Sci (2011) 1.37
Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol (2009) 1.36
Brown adipose tissue in adult humans: a metabolic renaissance. Endocr Rev (2013) 1.34
Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol (2011) 1.34
C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation (2003) 1.34
Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans. Nutr Metab (Lond) (2012) 1.33
Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol (2006) 1.32
Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med (2007) 1.30
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res (2006) 1.28
Adipose tissue dysfunction in nascent metabolic syndrome. J Obes (2013) 1.26
Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis (2009) 1.26
Functional sympatholysis is impaired in hypertensive humans. J Physiol (2011) 1.25
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol (2007) 1.25
Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab (2011) 1.25
Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes (2002) 1.24
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology (2008) 1.24